Epidemiology of Resistant Microbial Strains Among Different Groups of People (Healthy, Infected and Exposed to Animals) (ABRESIST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03343119 |
Recruitment Status : Unknown
Verified October 2018 by Kaidi Telling, University of Tartu.
Recruitment status was: Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : October 11, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
ESBL Producing E.Coli ESBL Producing K.Pneumoniae Multidrug Resistant P.Aeruginosa Carbapenem Resistant P.Aeruginosa Methicillin Resistant Staphylococcus Aureus (MRSA) Vancomycin (Glycopeptide) Resistant Enterococcus (VRE) |
Study Type : | Observational |
Actual Enrollment : | 708 participants |
Observational Model: | Ecologic or Community |
Time Perspective: | Other |
Official Title: | Transfer Routes of Antibiotic Resistance |
Actual Study Start Date : | March 27, 2012 |
Actual Primary Completion Date : | January 30, 2014 |
Estimated Study Completion Date : | August 2019 |
Group/Cohort |
---|
Hospitalised patients
No intervention
|
Healthy volunteers
No intervention
|
Dog owners (healthy volunteers)
No intervention
|
Veterinarians (healthy volunteers)
No intervention
|
Pig farmers (healthy volunteers)
No intervention
|
- Colonization rate with multiresistant (MDR) bacteria in hospitalized patients [ Time Frame: March 2012 - March 2014 ]To evaluate the impact of hospitalization for carriage and infection rate with MDR bacteria
- Colonization rate with multiresistant (MDR) bacteria in healthy humans [ Time Frame: March 2012 - March 2014 ]To evaluate the impact of animal exposure for carriage rate with MDR bacteria
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
I group All individuals who have been hospitalised and have been diagnosed carriage or infection with multiresistant bacteria listed above.
II group Children >6 months of age and all adults who have not been hospitalised or received antibacterial treatment in previous 3 months.
I group Hospitalised patients Inclusion Criteria
- MDR bacteria (listed above) isolated from clinical specimen
- hospitalisation to the Tartu University Hospital or North Estonia Medical Centre or West Tallinn Central Hospital or East-Tallinn Central Hospital or The Hospital of Reconstructive Surgery
II group Healthy volunteers Inclusion Criteria
- age >6 months
- have not received any antibacterial treatment in previous 3 months
- have not been hospitalised in previous 3 months
III group Dog owners Inclusion Criteria
- age >6 months
- have not received any antibacterial treatment in previous 3 months
- have not been hospitalised in previous 3 months
- owning a dog
IV group veterinarians Inclusion Criteria
- have not received any antibacterial treatment in previous 3 months
- have not been hospitaliZed in previous 3 months
- working as a veterinarian
V group pig farmers Inclusion Criteria
- have not received any antibacterial treatment in previous 3 months
- have not been hospitalized in previous 3 months
- occupation as a pig farmer

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03343119
Study Director: | Tanel Tenson, PhD | University of Tartu |
Responsible Party: | Kaidi Telling, MD, University of Tartu |
ClinicalTrials.gov Identifier: | NCT03343119 |
Other Study ID Numbers: |
SLOTI12038T |
First Posted: | November 17, 2017 Key Record Dates |
Last Update Posted: | October 11, 2018 |
Last Verified: | October 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Pneumonia Respiratory Tract Infections Infections Lung Diseases Respiratory Tract Diseases |